

**PCT**ORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 31/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/15211</b> <b>(43) International Publication Date:</b> 23 March 2000 (23.03.00)
<b>(21) International Application Number:</b> PCT/US99/21377 <b>(22) International Filing Date:</b> 17 September 1999 (17.09.99) <b>(30) Priority Data:</b> 09/156,102 17 September 1998 (17.09.98) US 60/126,489 26 March 1999 (26.03.99) US <i>17 Mar 01 / 30 Mar 01</i> <b>(71) Applicant (for all designated States except US):</b> AKESIS PHARMACEUTICALS, INC. [US/US]; Suite B, 10565 Science Center Drive, San Diego, CA 92121 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> FINE, Stuart [US/US]; 2230 White Oak Drive, Northbrook, IL 60062 (US). KINSELLA, Kevin [US/US]; 1735 Castellana Road, La Jolla, CA 92037 (US). <b>(74) Agents:</b> TAFT, Kingsley, L. et al.; Foley, Hoag & Eliot, LLP, One Post Office Square, Boston, MA 02109 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> COMPOSITIONS AND METHODS FOR TREATMENT OF GLUCOSE METABOLISM DISORDERS  <b>(57) Abstract</b>  Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.		